Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders

Alfonso Quintás-Cardama; Hagop M. Kantarjian; Francis Giles; Srdan Verstovsek

doi:10.1055/s-2006-942761

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2006; 32(4): 409-416
DOI: 10.1055/s-2006-942761

Pegylated Interferon Therapy for Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders

Alfonso Quintás-Cardama¹ , Hagop M. Kantarjian¹ , Francis Giles¹ , Srdan Verstovsek¹

¹The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Abstract

ABSTRACT

The conventional management of patients with high-risk Philadelphia chromosome-negative (Ph-negative) myeloproliferative disorders (MPDs) revolves around the administration of cytoreductive agents such as hydroxyurea, anagrelide, and recombinant human interferon α (IFN-α). IFN-α has shown significant activity in the treatment of chronic myelogenous leukemia (CML) and Ph-negative MDPs. However, the response rates of IFN-α therapy frequently have been hampered by high dropout rates due to side effects and inconvenient dosing schedules. Pegylated (PEG) IFN-α is formulated by covalently attaching polymers of ethylene glycol of large molecular weight to the native IFN-α molecule. Such chemical modification increases serum half-life, decreases renal excretion, and results in prolonged patient exposure to PEG-IFN-α, thus allowing for weekly administration while maintaining acceptable toxicity, tolerability, and activity profiles. The lack of adequate therapies for patients with MPDs and the superior pharmacokinetic and pharmacodynamic profile of PEG-IFN-α relative to standard IFN-α has prompted the investigation of the activity and safety of PEG-IFN-α in patients with essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis. We summarize the available data on the use of PEG-IFN-α in patients with Ph-negative MPDs.

KEYWORDS

Interferon - pegylated interferon - myeloproliferative disorders - therapy - clinical trials

Full Text

References

REFERENCES

1 Talpaz M, Mavligit G, Keating M et al.. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983; 99 789-792
2 Talpaz M, Kantarjian H M, McCredie K et al.. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986; 314 1065-1069
3 Silver R T. A new treatment for polycythemia vera: recombinant interferon (rIFN) alfa-2b. Blood. 1988; 72 XX (abst 227a)
4 Gilbert H S. Persistence of remission of myeloid metaplasia after treatment with recombinant interferon alpha-2b. Blood. 1988; 72 XX (abst 200a)
5 Velu T, Delwiche F, Flament J et al.. Therapy of essential thrombocythemia with human alpha 2 recombinant interferon. Blood. 1984; 64 XX (abst 176)
6 Gilbert H S. Regression of myeloid metaplasia during IFN-α-2b treatment of myeloproliferative disease is accompanied by reduction in circulating concentrations of colony-stimulating factor-1. Clin Res. 1989; 37 XX (abst 545A)
7 Gilbert H S. Long term treatment of myeloproliferative disease with interferon-α. Cancer. 1998; 83 (6) 1205-1213
8 Wills R J. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990; 19 390-399
9 Barouki F M, Witter F R, Griffin D E et al.. Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy ren. J Interferon Res. 1987; 7 29-39
10 Nucci M L, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev. 1991; 6 133-151
11 Goeddel D V, Yelverton E, Ulrich A et al.. Human leukocyte interferon produced in E. Coli. Nature. 1980; 287 411-416
12 Bailon P, Schaffer C A, Spence C et al.. Long lasting forms of polyethylene glycol conjugated interferon α-2a. Roche Research Report N-130915 May 3, 1996 Hoffmann-La Roche Nutley, NJ;
13 Ackrill A M. Studies on the in vitro biological activities of PEG-IFN (Ro 25-8310), with reference to Roferon-A (Ro 25-8181): University of Toronto. Research Report W-143195. November 22, 1999 Hoffmann-La Roche Nutley, NJ;
14 Certa U. Gene expression patterns of interferon alpha or peginterferon alfa-2a stimulated human melanoma cells using DNA microarrays. Research Report 1005805. August 3, 2001 Hoffmann-La Roche Nutley, NJ;
15 Laxton C, Gilbert S, Ackrill A et al.. Induction of the interferon-inducible human gene, 6-16, by Roferon®-A (Ro 25-8181) and peginterferon alfa-2a (Ro-25-8310). Research Report W-143166 August 12, 1999 Hoffmann-La Roche Nutley, NJ;
16 Palleroni A V, Dvorozniak M T, Aglione A. Antiproliferative and antitumor activity of pegylated interferon alpha (Ro 25-8310). Research Report N-181005 January 31, 1998 Hoffmann-La Roche Nutley, NJ;
17 Stremlo D, Khan A et al.. Antiproliferative activity of pegylated interferon alpha (Ro 25-8310). Research Report N-181539 February 2000 Hoffmann-La Roche Nutley, NJ;
18 Holzknecht B, Bosley F, Greway A T. The pharmacokinetics and pharmacodynamics of PEG2-IFN (Ro 25-8310) and ROFERON® A (Ro 22-8181) in the female cynomolgus monkey, following single subcutaneous administrations of PEG2-IFN or ROFERON® A (D95111). Research Report N-138704 October 10, 1996 Hoffmann-La Roche Nutley, NJ;
19 Glue P, Fang J W, Rouzier-Panis R et al.. Pegylated interferon-α-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000; 68 556-567
20 Aglione A, Bailon P S, Dvorozniak M T et al.. Immunogenicity of pegylated recombinant human interferon alpha 2a candidates in mice. Research Report N-138888 July 22, 1996 Hoffmann-La Roche Nutley, NJ;
21 Slater C, Bohoslawec O, Eliahou C. A two-week study of the effect of a Filgrastim (Neupogen) subcutaneous treatment regimen on the reversal of PEG-IFNα2aαA/D induced neutropenia in female mice (study no. 07041). Research Report N-181361 Hoffmann-La Roche Nutley, NJ;
22 Catala A R, Eliahou C B. Ro 25-8310 (PEG-IFN α-2a): Safety pharmacology (Quintiles Scotland Limited, study no. DHA02201-02210, Roche study no. 06938). Research Report N-139406 October 6, 1997 Hoffmann-La Roche Nutley, NJ;
23 Bailon P S, Palleroni A V, Hoffman-La Roche A G , inventors.. Interferon conjugates. European patent EP 0 809996 A2. 1997;
24 Data on file. Investigator's Brochure: information for the investigational product SCH 54031, PEG-Intron (peginterferon alfa-2b). Kenilworth, NJ; Schering-Plough Research Institute 2000
25 Pelleroni A V, Aglione A, Dvorozniak M T et al.. The in vivo fate of PEG-interferon alpha-2a (Ro 25-3036) in tumor bearing mice. Paper presented at: the Annual Meeting of the American Association for Cancer Research April 10-13, 1994 San Francisco, CA; (abst 310)
26 Hoffmann-La Roche AG Press Release, November 8, 1999. Pegasys posts positive results in chronic hepatitis C patients with cirrhosis. Nutley, NJ; Hoffmann-La Roche
27 Rothstein K D, Perrillo R P, Imperial J et al.. Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN alpha-2a (PEGASYS) or standard interferon alfa-2b/ribavirin (REBETRON) combination therapy. Gastroenterology. 2001; 120 (suppl 1; abst 16)
28 Kibble A. Digestive disease week (Part I), Orlando, FL. Investigational Drug Database Meeting Report May 16-19, 1999
29 Truitt G A, Tarby C M, Stem L L et al.. Pharmacodynamic and preliminary pharmacokinetic evaluation of PEGylated derivatives of interferon-alpha 2a. Proc Am Assoc Cancer Res. 1994; 35 (abst 2370)
30 Hoffmann-La Roche Inc Press Release 1999 May 16. Dosing of Pegasys is comparable for cirrhotic and non-cirrhotic chronic hepatitis C patients. Nutley, NJ; Hoffmann-La Roche
31 Modi M W, Fulton J S, Buckmann D K et al.. Clearance of pegylated (40 kDa) interferon alfa-2a (PEGASYS™) is primarily hepatic. Hepatology. 2000; 32 371a
32 Staudner H, Eliahou C B, Moore D et al.. Ro 25-8310 (PEG-IFN): A study of the effects of Ro 25-8310 on sex steroid hormones on female cynomolgus monkey. Research Report N-181442 March 7, 2000 Hoffmann-La Roche Nutley, NJ;
33 Talpaz M, Rakhit A, Rittweger K et al.. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005; 11(17) 6247-6255
34 Multiple rising-dose safety and tolerance of PEG12000-Interferon alfa-2b (SCH 54031) administered subcutaneously in patients with chronic hepatitis C (data on file as I95-060-01). Kenilworth, NJ; Schering-Plough
35 Lindsay K L, Trepo C, Heintges T et al.. A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34 395-403
36 Buckmann D K, Fulton J. Ro 25-8310: Distribution and metabolism of PEG-IFN alfa-2a after single and multiple administrations to male rats. RR 1002849, 2001 Hoffmann-La Roche Nutley, NJ;
37 Fulton J, Buckmann D K. Mass Balance and tissue distribution after single i.v. and s.c. administration of [14C] PEG-IFN (14C Ro 25-8310) to male rats. Research Report N-181400. February 11, 2000 Hoffmann-La Roche Nutley, NJ;
38 Talpaz M, O'Brien S, Rose E et al.. Phase I study of polyethylene glycol formulation of interferon alpha-2b; (PEG Intron; Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001; 98 1708-1713
39 Rosti G, Trabacchi E, Bassi S et al.. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica. 2003; 88(3) 256-259
40 Baccarani M, Martinelli G, Rosti G et al.. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood. 2004; 104(13) 4245-4251
41 Garcia-Manero G, Talpaz M, Giles F J et al.. Treatment of Philadelphia chromosome-positive chronic myelogenous leucemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer. 2003; 97(12) 3010-3016
42 Cervantes F, Camos M, Boque C et al.. Polyethylene glycol interferon-α2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia. Haematologica. 2004; 89 870-871
43 Cortes J, Talpaz M, O'Brien S et al.. A randomized trial of high-dose (HD) imatinib mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as frontline therapy for patients with chronic myeloid leucemia (CML) in early chronic phase (CP). Blood. 2005; 106 316(abst 1084)
44 Kiladjian J J, Cassinat B, Turlure P et al.. PVN1: A Phase 2 Study of Pegylated Interferon-α-2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety. Blood. 2005; 106 315(abst 4940)
45 Alvarado Y, Cortes J, Vertovsek S et al.. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003; 51(1) 81-86
46 Langer C, Lengfelder E, Thiele J et al.. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005; 90(10) 1333-1338
47 Gugliotta L, Bulgarelli S, Vianelli N et al.. PEG Intron treatment in 90 patients with essential thrombocythemia (ET) final report of a phase II study. Blood. 2005; 106 731a (abst 2600)
48 Gugliotta L, Bulgarelli S, Asioli S et al.. Bone marrow evaluation according to the PVSG and WHO Criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Preliminary results. Blood. 2005; 106 316 (abst 4962)
49 Samuelsson J, Hasselbalch H, Bruserud O et al.. Phase II Trial of pegylated interferon α-2b in polycythemia vera and essential thrombocythemia. Clinical responses, effects on PRV-1 expression and impact on quality of life. Blood. 2004; 104 425a (abst 1518)
50 Verstovsek S, Lawhorn K, Giles F et al.. PEG-Intron for myeloproliferative diseases: an update of ongoing phase II study. Blood. 2004; 104 13a (abst 33)
51 Lipton J H, Khoroshko N D, Golenkov A N et al.. A randomized multicenter comparative study of peginterferon alfa-2a (40KD) vs interferon-alfa-2a in patients with treatment-naïve chronic-phase chronic myelogenous leukemia. Blood. 2002; 100 782a (abst 3091)-0
52 Michallet M, Maloisel F, Delain M et al.. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004; 18(2) 309-315
53 Harrison C N, Campbell P J, Buck G et al.. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353 33-45

Srdan VerstovsekM.D. Ph.D.

The University of Texas M.D. Anderson Cancer Center, Department of Leukemia

Unit 428, 1515 Holcombe Blvd., Houston, TX 77030

Email: sverstov@mdanderson.org